Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389

1.

TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.

Suenaga Y, Yamamoto M, Sakuma T, Sasada M, Fukai F, Ohira M, Yamaguchi Y, Yamamoto T, Ando K, Ozaki T, Nakagawara A.

Biochem Biophys Res Commun. 2019 Oct 15;518(2):311-318. doi: 10.1016/j.bbrc.2019.08.052. Epub 2019 Aug 17.

PMID:
31427086
2.

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.

Ando K, Nakamura Y, Nagase H, Nakagawara A, Koshinaga T, Wada S, Makishima M.

Int J Mol Sci. 2019 Jul 29;20(15). pii: E3700. doi: 10.3390/ijms20153700.

3.

Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.

Iehara T, Yoneda A, Yokota I, Takahashi H, Teramukai S, Kamijyo T, Nakazawa A, Takimoto T, Kikuta A, Yagyu S, Ikeda H, Nakagawara A, Tajiri T; Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

Pediatr Blood Cancer. 2019 Nov;66(11):e27914. doi: 10.1002/pbc.27914. Epub 2019 Jul 24.

PMID:
31342649
4.

Pediatric patients with cancer predisposition in Japan: Results of a questionnaire survey.

Nakano Y, Tsunematsu Y, Yamazaki F, Manabe A, Nakagawara A, Hiyama E, Kumamoto T.

Pediatr Blood Cancer. 2019 Oct;66(10):e27937. doi: 10.1002/pbc.27937. Epub 2019 Jul 19. No abstract available.

PMID:
31322809
5.

Programmed expression of pro-apoptotic BMCC1 during apoptosis, triggered by DNA damage in neuroblastoma cells.

Islam MS, Takano R, Yokochi T, Akter J, Nakamura Y, Nakagawara A, Tatsumi Y.

BMC Cancer. 2019 Jun 6;19(1):542. doi: 10.1186/s12885-019-5772-4.

6.

Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG.

Pediatr Blood Cancer. 2019 Aug;66(8):e27819. doi: 10.1002/pbc.27819. Epub 2019 May 21.

PMID:
31115156
7.

Tumor suppressor KIF1Bβ regulates mitochondrial apoptosis in collaboration with YME1L1.

Ando K, Yokochi T, Mukai A, Wei G, Li Y, Kramer S, Ozaki T, Maehara Y, Nakagawara A.

Mol Carcinog. 2019 Jul;58(7):1134-1144. doi: 10.1002/mc.22997. Epub 2019 Mar 11.

8.

Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region.

Izumi H, Li Y, Shibaki M, Mori D, Yasunami M, Sato S, Matsunaga H, Mae T, Kodama K, Kamijo T, Kaneko Y, Nakagawara A.

Sci Rep. 2019 Feb 19;9(1):2236. doi: 10.1038/s41598-019-39229-8.

9.

PPP3CB contributes to poor prognosis through activating nuclear factor of activated T-cells signaling in neuroblastoma.

Shakhova I, Li Y, Yu F, Kaneko Y, Nakamura Y, Ohira M, Izumi H, Mae T, Varfolomeeva SR, Rumyantsev AG, Nakagawara A.

Mol Carcinog. 2019 Mar;58(3):426-435. doi: 10.1002/mc.22939. Epub 2018 Dec 13.

PMID:
30457174
10.

Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A; Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

Int J Clin Oncol. 2018 Oct;23(5):965-973. doi: 10.1007/s10147-018-1281-8. Epub 2018 Apr 26.

PMID:
29700636
11.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

12.

EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.

Li Z, Takenobu H, Setyawati AN, Akita N, Haruta M, Satoh S, Shinno Y, Chikaraishi K, Mukae K, Akter J, Sugino RP, Nakazawa A, Nakagawara A, Aburatani H, Ohira M, Kamijo T.

Oncogene. 2018 May;37(20):2714-2727. doi: 10.1038/s41388-018-0133-3. Epub 2018 Mar 6.

13.

Neuroblastoma.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M.

Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241. doi: 10.1093/jjco/hyx176. Review.

PMID:
29378002
14.

Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J.

Oncotarget. 2017 Nov 18;8(64):107513-107529. doi: 10.18632/oncotarget.22495. eCollection 2017 Dec 8.

15.

Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx062.

PMID:
29059438
16.

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A.

Oncotarget. 2017 May 23;8(34):56684-56697. doi: 10.18632/oncotarget.18079. eCollection 2017 Aug 22.

17.

Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller LR, Brodeur GM.

Clin Cancer Res. 2017 Jul 1;23(13):e98-e106. doi: 10.1158/1078-0432.CCR-17-0652. Review.

18.

Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk.

Villani A, Greer MC, Kalish JM, Nakagawara A, Nathanson KL, Pajtler KW, Pfister SM, Walsh MF, Wasserman JD, Zelley K, Kratz CP.

Clin Cancer Res. 2017 Jun 15;23(12):e83-e90. doi: 10.1158/1078-0432.CCR-17-0631. Review.

19.

Neuroblastoma.

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA.

Nat Rev Dis Primers. 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78. Review.

PMID:
27830764
20.

Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.

Ho WL, Hsu WM, Huang MC, Kadomatsu K, Nakagawara A.

J Hematol Oncol. 2016 Sep 29;9(1):100. Review.

21.

Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.

Satoh S, Takatori A, Ogura A, Kohashi K, Souzaki R, Kinoshita Y, Taguchi T, Hossain MS, Ohira M, Nakamura Y, Nakagawara A.

Sci Rep. 2016 Sep 8;6:32682. doi: 10.1038/srep32682.

22.

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.

Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H.

PLoS One. 2016 Aug 11;11(8):e0161039. doi: 10.1371/journal.pone.0161039. eCollection 2016.

23.

Transcriptional regulation of BMCC1 mediated by E2F1 in neuroblastoma cells.

Islam MS, Tatsumi Y, Takano R, Yokochi T, Akter J, Ozaki T, Nakamura Y, Ohira M, Nakagawara A.

Biochem Biophys Res Commun. 2016 Sep 9;478(1):81-86. doi: 10.1016/j.bbrc.2016.07.089. Epub 2016 Jul 22.

PMID:
27453342
24.

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17.

PMID:
27434878
25.

Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.

Sheikh A, Takatori A, Hossain MS, Hasan MK, Tagawa M, Nagase H, Nakagawara A.

Cancer Sci. 2016 Sep;107(9):1223-32. doi: 10.1111/cas.13003. Epub 2016 Sep 2.

26.

Effects of novel small compounds targeting TrkB on neuronal cell survival and depression-like behavior.

Fukuda M, Takatori A, Nakamura Y, Suganami A, Hoshino T, Tamura Y, Nakagawara A.

Neurochem Int. 2016 Jul;97:42-8. doi: 10.1016/j.neuint.2016.04.017. Epub 2016 May 7.

PMID:
27166149
27.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.

Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28.

28.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

29.

Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells.

Islam SM, Suenaga Y, Takatori A, Ueda Y, Kaneko Y, Kawana H, Itami M, Ohira M, Yokoi S, Nakagawara A.

Cancer Sci. 2015 Oct;106(10):1351-61. doi: 10.1111/cas.12746. Epub 2015 Aug 18.

30.

Oncogenic Lmo3 cooperates with Hen2 to induce hydrocephalus in mice.

Isogai E, Okumura K, Saito M, Yoshizawa Y, Itoh K, Tando S, Ohira M, Haraguchi S, Nakagawara A, Fushiki S, Nagase H, Wakabayashi Y.

Exp Anim. 2015;64(4):407-14. doi: 10.1538/expanim.15-0026. Epub 2015 Jul 6.

31.

NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.

Shoji W, Suenaga Y, Kaneko Y, Islam SM, Alagu J, Yokoi S, Nio M, Nakagawara A.

Biochem Biophys Res Commun. 2015 Jun 5;461(3):501-6. doi: 10.1016/j.bbrc.2015.04.050. Epub 2015 Apr 17.

32.

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.

Kaneko Y, Suenaga Y, Islam SM, Matsumoto D, Nakamura Y, Ohira M, Yokoi S, Nakagawara A.

Cancer Sci. 2015 Jul;106(7):840-7. doi: 10.1111/cas.12677. Epub 2015 May 19.

33.

Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma.

Nakazawa A, Haga C, Ohira M, Okita H, Kamijo T, Nakagawara A.

Cancer Sci. 2015 Jun;106(6):766-71. doi: 10.1111/cas.12665. Epub 2015 Apr 22.

34.

BMCC1, which is an interacting partner of BCL2, attenuates AKT activity, accompanied by apoptosis.

Tatsumi Y, Takano R, Islam MS, Yokochi T, Itami M, Nakamura Y, Nakagawara A.

Cell Death Dis. 2015 Jan 22;6:e1607. doi: 10.1038/cddis.2014.568.

35.

Intracellular fragment of NLRR3 (NLRR3-ICD) stimulates ATRA-dependent neuroblastoma differentiation.

Akter J, Takatori A, Islam MS, Nakazawa A, Ozaki T, Nagase H, Nakagawara A.

Biochem Biophys Res Commun. 2014 Oct 10;453(1):86-93. doi: 10.1016/j.bbrc.2014.09.065. Epub 2014 Sep 23.

PMID:
25256744
36.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

37.

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG.

J Clin Oncol. 2014 Oct 1;32(28):3169-76. doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25.

38.

Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.

Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR.

Pediatr Blood Cancer. 2014 Nov;61(11):1932-9. doi: 10.1002/pbc.25134. Epub 2014 Jul 7.

PMID:
25044743
39.

Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation.

Shimozato O, Waraya M, Nakashima K, Souda H, Takiguchi N, Yamamoto H, Takenobu H, Uehara H, Ikeda E, Matsushita S, Kubo N, Nakagawara A, Ozaki T, Kamijo T.

Oncogene. 2015 Apr 9;34(15):1949-60. doi: 10.1038/onc.2014.141. Epub 2014 Jun 2.

PMID:
24882578
40.

Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association.

Tomiyama A, Uekita T, Kamata R, Sasaki K, Takita J, Ohira M, Nakagawara A, Kitanaka C, Mori K, Yamaguchi H, Sakai R.

Cancer Res. 2014 Jul 15;74(14):3790-801. doi: 10.1158/0008-5472.CAN-14-0241. Epub 2014 May 15.

41.

RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.

Haruta M, Kamijo T, Nakagawara A, Kaneko Y.

Cancer Lett. 2014 Jun 28;348(1-2):167-76. doi: 10.1016/j.canlet.2014.03.022. Epub 2014 Mar 26.

PMID:
24680815
42.

Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

J Clin Oncol. 2014 Apr 20;32(12):1228-35. doi: 10.1200/JCO.2013.53.6342. Epub 2014 Mar 24.

43.

Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.

Yamaguchi Y, Takenobu H, Ohira M, Nakazawa A, Yoshida S, Akita N, Shimozato O, Iwama A, Nakagawara A, Kamijo T.

Eur J Cancer. 2014 May;50(8):1555-65. doi: 10.1016/j.ejca.2014.01.023. Epub 2014 Feb 19.

PMID:
24559687
44.

Identification of novel candidate compounds targeting TrkB to induce apoptosis in neuroblastoma.

Nakamura Y, Suganami A, Fukuda M, Hasan MK, Yokochi T, Takatori A, Satoh S, Hoshino T, Tamura Y, Nakagawara A.

Cancer Med. 2014 Feb;3(1):25-35. doi: 10.1002/cam4.175. Epub 2014 Jan 1.

45.

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

Suenaga Y, Islam SM, Alagu J, Kaneko Y, Kato M, Tanaka Y, Kawana H, Hossain S, Matsumoto D, Yamamoto M, Shoji W, Itami M, Shibata T, Nakamura Y, Ohira M, Haraguchi S, Takatori A, Nakagawara A.

PLoS Genet. 2014 Jan;10(1):e1003996. doi: 10.1371/journal.pgen.1003996. Epub 2014 Jan 2.

46.

[A novel role of RUNX2 in the regulation of p53-dependent DNA damage response].

Ozaki T, Nakagawara A, Nagase H.

Seikagaku. 2013 Nov;85(11):1002-7. Review. Japanese. No abstract available.

PMID:
24364254
47.

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.

Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y, Hossain S, Akter J, Ogura A, Nakamura Y, Kadomatsu K, Nakagawara A.

Sci Rep. 2013 Dec 20;3:3450. doi: 10.1038/srep03450.

48.

NFBD1/MDC1 is phosphorylated by PLK1 and controls G2/M transition through the regulation of a TOPOIIα-mediated decatenation checkpoint.

Ando K, Ozaki T, Hirota T, Nakagawara A.

PLoS One. 2013 Dec 11;8(12):e82744. doi: 10.1371/journal.pone.0082744. eCollection 2013.

49.

Two cases of neuroblastoma comprising two distinct clones.

Yamazaki F, Nakazawa A, Osumi T, Shimojima N, Tanaka T, Nakagawara A, Shimada H.

Pediatr Blood Cancer. 2014 Apr;61(4):760-2. doi: 10.1002/pbc.24779. Epub 2013 Sep 20.

PMID:
24108545
50.

RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response.

Ozaki T, Nakagawara A, Nagase H.

Int J Genomics. 2013;2013:271347. doi: 10.1155/2013/271347. Epub 2013 Sep 3. Review.

Supplemental Content

Loading ...
Support Center